Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEWRON PHARMACEUTICALS S.P.A.

(NWRN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE : Newron Receives Fifth Tranche from Financing Agreement with European Investment Bank (EIB)

10/18/2021 | 11:46am EST

DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Financing/Miscellaneous Newron Receives Fifth Tranche from Financing Agreement with European Investment Bank (EIB) 2021-10-18 / 17:45 The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

Newron Receives Fifth Tranche from Financing Agreement with European Investment Bank (EIB)

Milan, Italy - October 18, 2021, 5:45 pm CEST - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that it has received Tranche 5 under its financing agreement with the European Investment Bank (EIB) that was signed in October 2018 and comprises up to EUR 40 million, subject to achieving a set of agreed performance criteria. The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment plan for Europe. Tranche 5 consists of EUR 7.5 million and will primarily be used to support the Company's development programs in diseases of the central nervous system. The first four tranches of the loan, totaling EUR 32.5 million, were received by Newron in 2019, 2020 and in September 2021.

In connection with Tranche 5, EIB has received warrants entitling it to purchase up to 151,344 ordinary shares of Newron at an exercise price of EUR 9.25 per share.

About Newron Pharmaceuticals Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago^(R)/safinamide has received marketing authorization for the treatment of Parkinson's disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Brazil, Colombia, Israel, the United Arab Emirates, Japan and South Korea, and is commercialized by Newron's Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. Newron is developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit: www.newron.com For more information Newron Stefan Weber - CEO, +39 02 6103 46 26, pr@newron.com

UK/Europe Simon Conway/ Natalie Garland-Collins, FTI Consulting, +44 (0)20 3727 1000, SCnewron@fticonsulting.com

Switzerland Valentin Handschin, IRF Reputation, +41 43 244 81 54, handschin@irf-reputation.ch

Germany/Europe Anne Hennecke/Caroline Bergmann, MC Services, +49 211 52925220, newron@mc-services.eu

USA Paul Sagan, LaVoieHealthScience, +1 617 374 8800, Ext. 112, psagan@lavoiehealthscience.com

-----------------------------------------------------------------------------------------------------------------------

2021-10-18 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

-----------------------------------------------------------------------------------------------------------------------

1241518 2021-10-18

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1241518&application_name=news

(END) Dow Jones Newswires

October 18, 2021 11:45 ET (15:45 GMT)

All news about NEWRON PHARMACEUTICALS S.P.A.
12/01Change in Newron Board of Directors
EQ
12/01Change in Newron Board of Directors
EQ
12/01Newron Pharmaceuticals S.p.A. Announces Resignation of Robert Leslie Holland as Non-Exe..
CI
10/18NEWRON PHARMACEUTICALS S P A : Gets $9 Million Under Financing Deal With European Investme..
MT
10/18NEWRON PHARMACEUTICALS S P A : Receives Fifth Tranche from Financing Agreement witháEurope..
EQ
10/18NEWRON PHARMACEUTICALS S P A : Receives Fifth Tranche from Financing Agreement with Europe..
EQ
10/18NEWRON PHARMACEUTICALS S P A : Receives Fifth Tranche from Financing Agreement with Europe..
BU
10/18Newron Pharmaceuticals S.p.A Receives Fifth Tranche from Financing Agreement with Europ..
CI
10/18Newron Pharmaceuticals S.p.A. announced that it has received Ç40 million in funding fro..
CI
09/16NEWRON PHARMACEUTICALS S P A : Announces Half-Year 2021 Results
BU
More news
Financials
Sales 2021 5,60 M 6,33 M 6,33 M
Net income 2021 -18,4 M -20,9 M -20,9 M
Net Debt 2021 11,5 M 13,0 M 13,0 M
P/E ratio 2021 -1,58x
Yield 2021 -
Capitalization 29,2 M 33,0 M 33,0 M
EV / Sales 2021 7,26x
EV / Sales 2022 10,6x
Nbr of Employees 23
Free-Float 95,0%
Chart NEWRON PHARMACEUTICALS S.P.A.
Duration : Period :
Newron Pharmaceuticals S.p.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEWRON PHARMACEUTICALS S.P.A.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 1,63 €
Average target price 4,58 €
Spread / Average Target 180%
EPS Revisions
Managers and Directors
Stefan Weber Chief Executive Officer & Director
Roberto Galli Vice President-Finance
Ulrich K÷stlin Non-Executive Chairman
Ravi Anand Chief Medical Officer
Luca Benatti Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
NEWRON PHARMACEUTICALS S.P.A.-20.93%33
CSL LIMITED7.81%98 819
WUXI BIOLOGICS (CAYMAN) INC.-0.29%55 833
SAMSUNG BIOLOGICS CO.,LTD.7.99%50 185
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-6.27%33 568